167017-55-2Relevant academic research and scientific papers
[1,2,4]triazolo[4,3-a]quinoxaline compounds
-
, (2008/06/13)
The present invention relates to [1,2,4]triazolo[4,3-a quinoxaline derivatives of formula I STR1 wherein one of R 1 and R 2 is a 5- or 6-membered nitrogen-containing heterocyclic ring which is optionally substituted with one, two or three substituents, wherein each substituent is independently phenyl or C 1-6 -alkyl, or one of R 1 and R 2 is a fused ring system comprising a 5- or 6-membered nitrogen-containing heterocyclic ring and a benzene, pyridine, pyrimidine or pyrazine ring, wherein the fused ring system is optionally substituted with phenyl or C 1-6 -alkyl; and the other of R 1 and R 2 is hydrogen, C 1-6 -alkyl, C 1-6 -alkoxy, halogen, NO 2, NH 2, CN, CF 3, COC 1-6 -alkyl or SO 2 NR''R"", wherein R'' and R"" are independently hydrogen or C 1-6 -alkyl; and X is O or S; and pharmaceutically acceptable salts thereof. The compounds have affinity for the AMPA receptors and are antagonists in connection with this type of receptors which makes them useful in the treatment of CNS ailments, especially in the treatment of any of the numerous indications caused by hyperactivity of excitatory amino acids.
